RedHill Biopharma Ltd. (RDHL) Income Statement
RDHL 2025 at a glance
Fiscal year ended December 31, 2025 · U.S. dollarsRDHL revenue and net income
Where RDHL's revenue goes
2025Each bar shows an amount and its share of revenue. RDHL kept −150.0% of revenue as net income.
RDHL profit margins
RDHL growth rates
to 2025| 1 year | 3 years | 5 years | 10 years | |
|---|---|---|---|---|
| Revenue | −96.4% | −83.3% | −66.2% | +57.7% |
| Gross profit | −94.1% | −78.4% | −59.9% | — |
| Operating income | — | — | — | — |
| Net income | — | — | — | — |
| EPS (diluted) | — | — | — | — |
1-year change and average annual growth (CAGR) over 3, 5 and 10 fiscal years. "—" when a starting value was zero or negative.
RDHL quarterly EPS vs estimates
RedHill Biopharma beat the analyst EPS estimate in 2 of the last 6 quarters.
RDHL income statement
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $286,000 | $8.0M | $6.5M | $61.8M | $85.8M | $64.4M | $6.3M | $8.4M | $4.0M | $101,000 |
| Cost of revenue | $0 | $3.2M | $3.5M | $33.3M | $49.4M | $36.9M | $2.3M | $2.8M | $2.1M | $30.5M |
| Gross profit | $286,000 | $4.9M | $3.1M | $28.5M | $36.4M | $27.5M | $4.0M | $5.5M | $1.9M | −$30.4M |
| Research & development | $2.0M | $1.6M | $3.5M | $7.3M | $29.5M | $16.5M | $17.4M | $24.9M | $33.0M | $25.2M |
| Sales, general & admin | $6.2M | $15.5M | $28.9M | $64.0M | $88.0M | $74.7M | $29.8M | $20.0M | $20.0M | $5.4M |
| Total operating expenses | $8.2M | $19.5M | −$9.6M | $71.3M | $117.5M | $91.2M | $47.2M | $44.9M | $53.9M | $30.6M |
| Operating income | −$7.9M | −$14.6M | $12.6M | −$42.8M | −$81.1M | −$63.7M | −$43.2M | −$39.3M | −$52.0M | −$30.5M |
| Interest income | $23,000 | $133,000 | $94,000 | $140,000 | $51,000 | $176,000 | $443,000 | $279,000 | $297,000 | $282,000 |
| Interest expense | $19,000 | $55,000 | $367,000 | $41.3M | $16.6M | $12.4M | $439,417 | $167,000 | $77,000 | $7,000 |
| Income before taxes | −$8.1M | −$8.3M | $23.9M | −$71.7M | −$97.7M | −$76.2M | −$42.3M | −$38.8M | −$45.5M | −$29.4M |
| Income taxes | — | — | −$2 | −$12.4M | $16.6M | $12.8M | $1.3M | $727,000 | $6.3M | $1.3M |
| Net income | −$429,000 | −$8.3M | $23.9M | −$71.7M | −$97.7M | −$76.2M | −$42.3M | −$38.8M | −$45.5M | −$29.4M |
| EBITDA | −$7.7M | −$7.6M | $26.3M | −$22.2M | −$63.0M | −$55.0M | −$40.7M | −$38.7M | −$45.5M | −$30.5M |
| EPS (diluted) | −$6.31 | −$204.22 | −$1.54 | −$90.40 | −$1650.00 | −$1040.52 | −$1300.00 | −$900.80 | −$1501.00 | −$2200.00 |
| Gross margin | 100.0% | 60.3% | 47.0% | 46.1% | 42.4% | 42.7% | 64.1% | 66.1% | 46.9% | −30,140.6% |
| Operating margin | −2,765.4% | −181.7% | 193.4% | −69.3% | −94.6% | −99.0% | −686.7% | −470.5% | −1,297.0% | −30,240.6% |
| Net margin | −150.0% | −102.8% | 366.2% | −116.0% | −114.0% | −118.4% | −672.5% | −464.4% | −1,136.6% | −29,079.2% |
| Jun '25 | Mar '25 | Sep '24 | Jun '24 | Mar '24 | Sep '23 | Jun '23 | Mar '23 | Dec '22 | Sep '22 | Jun '22 | Mar '22 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $2.0M | $2.0M | $2.7M | $1.3M | $1.3M | $567,500 | $1.8M | $12.8M | $12.8M | $17.6M | $18.3M | $13.1M |
| Cost of revenue | $803,500 | $803,500 | $894,000 | $702,000 | $702,000 | $520,499 | $806,000 | $8.6M | $8.6M | $9.5M | $9.0M | $6.3M |
| Gross profit | $1.2M | $1.2M | $1.8M | $584,000 | $584,000 | $47,000 | $990,000 | $4.2M | $4.2M | $8.1M | $9.4M | $6.8M |
| Research & development | $482,000 | $482,000 | $464,500 | $329,500 | $329,500 | $598,500 | $1.2M | $1.1M | $1.1M | $1.6M | $1.5M | $3.1M |
| Sales, general & admin | $2.9M | $2.9M | $3.3M | $4.5M | $4.5M | $3.4M | $3.5M | $32.9M | $32.9M | $13.6M | $17.0M | $20.4M |
| Total operating expenses | $3.4M | $3.4M | $4.9M | $4.8M | $4.8M | $6.1M | $5.4M | $14.1M | $14.1M | $15.2M | $18.5M | $23.4M |
| Operating income | −$2.2M | −$2.2M | −$3.1M | −$4.2M | −$4.2M | −$6.0M | −$4.4M | −$9.9M | −$9.9M | −$7.1M | −$9.2M | −$16.6M |
| Interest income | — | — | — | — | — | — | $7.1M | $21.6M | $4.7M | $3.2M | $1.7M | $10,000 |
| Interest expense | $512,000 | $512,000 | — | $874,000 | $874,000 | — | $1.9M | $1.4M | $1.4M | $31.8M | $4.2M | $3.9M |
| Income before taxes | −$2.1M | −$2.1M | −$2.6M | −$1.5M | −$1.5M | −$13.5M | $761,000 | −$3.7M | −$3.7M | −$35.7M | −$11.7M | −$20.5M |
| Income taxes | — | — | — | — | — | — | $421,000 | −$6.2M | −$6.2M | $28.6M | $2.6M | $10,000 |
| Net income | −$2.1M | −$2.1M | −$2.6M | −$1.5M | −$1.5M | −$13.5M | $761,000 | −$3.7M | $2.5M | −$35.7M | −$14.3M | −$20.5M |
| EBITDA | −$2.1M | −$2.1M | −$1.8M | −$4.0M | −$4.0M | −$5.8M | $2.7M | −$294,000 | −$294,000 | −$1.8M | −$5.6M | −$14.5M |
| EPS (diluted) | −$2.29 | −$4.02 | $0.00 | −$200.00 | −$0.20 | $0.00 | $0.26 | −$1.60 | −$0.20 | −$60.00 | −$0.20 | −$30.00 |
| Gross margin | 60.6% | 60.6% | 67.3% | 45.4% | 45.4% | 8.3% | 55.1% | 32.8% | 32.8% | 46.2% | 51.0% | 52.0% |
| Operating margin | −107.3% | −107.3% | −112.7% | −328.5% | −328.5% | −1,060.8% | −245.4% | −77.7% | −77.7% | −40.5% | −49.9% | −126.9% |
| Net margin | −101.3% | −101.3% | −94.7% | −120.1% | −120.1% | −2,386.4% | 42.4% | −29.1% | 19.5% | −203.4% | −77.7% | −156.7% |
Quarterly columns are labeled by the month the quarter ended. Figures in U.S. dollars as reported in RDHL's financial statements (latest annual report filed April 27, 2026); data from EODHD. Sales, general & administrative expenses include sales and marketing.
RDHL financial results
In fiscal year 2025 (ended December 31, 2025), RedHill Biopharma reported revenue of $0.3 million, down 96.4% from the year before. It had a net loss of $0.4 million, a net profit margin of −150.0%. Diluted earnings per share came to −$6.31. Over five years revenue grew at an average rate of −66.2% a year.
See the RDHL stock overview for the latest quote and news, or the RDHL chart for price history and technical indicators.
RDHL income statement FAQ
What is RedHill Biopharma's annual revenue?
RedHill Biopharma reported total revenue of $0.3 million for fiscal year 2025, which ended on December 31, 2025. That was down 96.4% from $8.0 million the previous year.
Is RedHill Biopharma profitable?
No. RedHill Biopharma reported a net loss of $0.4 million in fiscal 2025, a net profit margin of −150.0%; its operating margin was −2,765.4%.
What is RedHill Biopharma's gross margin?
RedHill Biopharma's gross margin was 100.0% in fiscal 2025: for every $100 of revenue, RedHill Biopharma kept $100 after the direct cost of its products and services.
How much does RedHill Biopharma spend on research and development?
RedHill Biopharma spent $2.0 million on research and development in fiscal 2025, 707.3% of revenue.
How fast is RedHill Biopharma growing?
Revenue grew −66.2% a year on average over the last five fiscal years, from $64.4 million to $0.3 million.
What are RedHill Biopharma's earnings per share?
RedHill Biopharma earned $-6.31 per diluted share in fiscal 2025, compared with $-204.22 a year earlier.
When does RedHill Biopharma's fiscal year end?
RedHill Biopharma's fiscal year ends in December. The latest annual report covers the year ended December 31, 2025 and was filed on April 27, 2026.